Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 597

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 597
---
. 001-35518).10.49*+Form of Performance Share Unit Award Agreement, for awards issued after 2024 under the Supernus Pharmaceuticals, Inc. Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company's Form 8-K filed on February 24, 2025, File No. 001-35518)10.50††*Settlement Agreement, dated as of April 30, 2024, by and between Supernus Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed on August 6, 2024).10.51**Contingent Value Rights Agreement, dated as of October 28, 2021, by and between Supernus Pharmaceuticals, Inc. and American Stock Transfer & Trust Company, LLC. (incorporated by reference to Index No. (d)(2)* to the Form SC TO-T/A filed on  November 23, 2021, File No.  005-88106).14 *Code of Ethics (incorporated by reference to Exhibit 14 to the Company's Form 8-K filed on December 20, 2024, File No. 001-35518).19 **Policy Statement on Securities Trades by Directors, Officers, and Employees. (incorporated by reference to Exhibit 19 to the Form 10-K filed on February 27, 2024, File No. 001-35518).21 **Subsidiaries of the Registrant.23.1 **Consent of KPMG LLP.31.1 **Certification of Chief Executive Officer.31.2 **Certification of Chief Financial Officer.32.1 **Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 135032.2 **Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 135097**Incentive Compensation Recoupment Policy.101 **The following financial information from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, formatted in Inline XBRL: (i) Cover Page; (ii) Consolidated Statement of Earnings; (iii) Consolidated Statement of Comprehensive Earnings; (iv) Consolidated Balance Sheets; (v)